WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2011139273) 4 SUBSTITUTED PYRAZOLOPYRIMIDINES USEFUL AS PKC-THETA INHIBITORS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2011/139273    International Application No.:    PCT/US2010/033711
Publication Date: 10.11.2011 International Filing Date: 05.05.2010
IPC:
C07D 487/04 (2006.01), A61K 31/519 (2006.01), A61P 37/00 (2006.01)
Applicants: VERTEX PHARMACEUTICALS INCORPORATED [US/US]; 130 Waverly Street Cambridge, MA 02139 (US) (For All Designated States Except US).
JIMENEZ, Juan-miguel [ES/GB]; (GB) (For US Only).
MILLER, Andrew [GB/GB]; (GB) (For US Only)
Inventors: JIMENEZ, Juan-miguel; (GB).
MILLER, Andrew; (GB)
Agent: KELLY, Susan, C.; VERTEX PHARMACEUTICALS INCORPORATED 130 Waverly Street Cambridge, MD 02139 (US)
Priority Data:
Title (EN) 4 SUBSTITUTED PYRAZOLOPYRIMIDINES USEFUL AS PKC-THETA INHIBITORS
(FR) PYRAZOLOPYRIMIDINES 4-SUBSTITUÉES POUVANT ÊTRE EMPLOYÉES EN TANT QU'INHIBITEURS DE PKC-THÊTA
Abstract: front page image
(EN)The present invention relates to compounds of formulae (I) and (IA) useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.
(FR)La présente invention concerne des composés de formule (I) et (IA) pouvant être employés en tant qu'inhibiteurs de protéine kinases. La présente invention concerne également des compositions de qualité pharmaceutique comprenant lesdits composés, et des méthodes d'emploi des compositions dans le traitement de diverses maladies, divers états pathologiques ou divers troubles. La présente invention concerne en outre des procédés de synthèse des composés selon l'invention.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)